Sonnet BioTherapeutics Holdings Inc. (SONN): Average Forecast Price

The development of Sonnet BioTherapeutics (SONN) relies on scientific achievements that render the company independent of market fluctuations. Stable demand for biotechnology transforms the asset into a defensive tool during a recession, as confirmed by the price chart on the GURU.Markets exchange with a value of 20.06. The business is based on the principles of bioethics and strict waste disposal control, ensuring full transparency of all clinical tests.

SONN (Sonnet BioTherapeutics Holdings Inc.) Price Target Chart history from 07/04/2022 to 12/13/2025

Metric breakdowns and analytics for Sonnet BioTherapeutics (SONN)

- price and consensus price forecast:

Market Chart sonnetbio.com|SONN - Price Target Chart

- stock exchange capitalization data:

Market Value Sonnet BioTherapeutics|SONN - Total Company Value

- shareholders' equity book value data:

Equity per Share Sonnet BioTherapeutics|SONN - Company Book Value|Capitalization to Book Value Ratio sonnetbio.com|SONN - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation multiples indicators:

SONN - Company Net Income|Expected Net Profit Sonnet BioTherapeutics|SONN - P/E Multiple|Forward Price to Earnings Multiple sonnetbio.com|SONN - Price/Earnings to Growth Multiple|Company Value to EBITDA Sonnet BioTherapeutics|SONN - Operating profit before deduction of amortization|Earnings per share for the trailing year Sonnet BioTherapeutics|SONN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months sonnetbio.com|SONN - Earnings per share growth in current year|Expected earnings per share growth for next year Sonnet BioTherapeutics

General company analysis:SONN (Sonnet BioTherapeutics Holdings, Inc.)

Mass-produced product of Sonnet BioTherapeutics Holdings, Inc.

To minimize capital risks, investors must filter out market noise by utilizing a weighted average asset valuation from leading experts. The unique oncology immunotherapy platform of Sonnet BioTherapeutics (SONN) ensures operational resilience, while the consensus valuation trend reflects collective business return expectations, allowing a smoothed retrospective to confirm the issuer's long-term fundamental reliability.

Competitors of Sonnet BioTherapeutics